Research team launches groundbreaking drug trial in Africa

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

It will be the first test of the anti-seizure medication , or LVT, for controlling caused by , a severe form of the disease that affects in some three million children, mostly in sub-Saharan Africa.

About one in 10 children who survive cerebral malaria are left with , said the trial's lead researcher Gretchen Birbeck, a professor of neurology and ophthalmology in the College of Osteopathic Medicine.

"This trial is aimed at improving seizure control with the hope of finding a path toward epilepsy prevention," Birbeck said. "Since oral LVT is relatively affordable for short-term use and feasibly could be delivered in resource-limited settings, this therapy could potentially be scaled up for broad use throughout malaria endemic ."

The trial will include about 40 children in Malawi. If all safety standards are met, dosage will be increased until 75 percent of the children are free of seizures for 24 hours.

A wireless EEG monitoring device the size of a deck of cards will tell the researchers if LVT is keeping the children seizure-free. Developed by New York-based biotechnology firm BioSignal Group, the device can be worn on the child's arm and transfers data in real-time to a computer, where it quickly can be analyzed and shared with colleagues.

"Unfortunately, many with cerebral malaria continue to have seizures with no clinical evidence that seizures are occurring, but their brains still are being affected," said Birbeck, who also is director of MSU's International Neurologic and Psychiatric Epidemiology Program. "To evaluate the effectiveness of LVT, we need continuous monitoring, which is very tough to do even in the best environment."

If the study finds a safe and effective dosage of LVT for cerebral malaria seizures, the team will scale it up and put the drug to the test in a randomized trial without the specialized technology.

The trial, part of MSU's Blantyre Malaria Project at Queen Elizabeth Central Hospital, is being funded with a nearly $2 million grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke.

It's part of a broader effort by Birbeck to, as she says, "bring epilepsy out of the shadows." The disease keeps many of its victims from holding a job or going to school, and the stigma associated with seizures prevent many of them from getting the treatment they need.

Birbeck is working in Malawi and Zambia to educate people about the disease so they aren't afraid to seek treatment. With her help, more and more patients are getting help and living productive lives.

Her ultimate goal is to find a way to keep people from getting epilepsy in the first place.

"The best legacy would be when they didn't need epilepsy treatment," she said. "That would be the nicest of all."

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.